View Older Stories

Jan 14, 2026 06:05AM BTIG Reiterates Buy Rating on Nurix (NRIX)

Jan 12, 2026 07:04AM NASDAQ: NRIX Nurix outlines 2026 goals for BTK degrader bexobrutideg

Jan 8, 2026 03:11AM Morgan Stanley Upgrades Nurix (NRIX) to Overweight

Jan 8, 2026 03:11AM Morgan Stanley Upgrades Nurix (NRIX) to Overweight

Dec 10, 2025 08:25AM Nurix (NRIX) PT Raised to $31 at H.C. Wainwright

Dec 10, 2025 04:13AM Nurix (NRIX) PT Raised to $30 at Mizuho

Dec 9, 2025 04:16AM Nurix (NRIX) PT Raised to $30 at BTIG

Dec 8, 2025 07:36AM Nurix's (NRIX) Bexdeg Potentially Best-in-Class - Stifel

Nov 7, 2025 09:02AM Nurix presents clinical data showing NX-1607 activates immune system

Oct 28, 2025 06:42AM Nurix (NRIX) PT Lowered to $28 at H.C. Wainwright

Oct 22, 2025 02:11PM Nurix (NRIX) PT Raised to $29 at RBC Capital

Oct 22, 2025 07:28AM Nurix begins pivotal study of bexobrutideg for blood cancer

Oct 20, 2025 04:06PM Mizuho Starts Nurix (NRIX) at Outperform, PT $24

Oct 20, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)

Oct 14, 2025 06:39AM Nurix (NRIX) PT Lowered to $33 at H.C. Wainwright

Oct 10, 2025 12:14PM Nurix (NRIX) PT Lowered to $33 at Stifel

Oct 10, 2025 08:19AM Nurix (NRIX) PT Lowered to $32 at Piper Sandler

Oct 10, 2025 05:22AM Nurix (NRIX) PT Lowered to $12 at Leerink Partners

Oct 9, 2025 04:02PM Nurix Therapeutics, Inc. (NRIX) Misses Q3 EPS by 20c

Sep 18, 2025 07:04AM Stifel Reiterates Buy Rating on Nurix (NRIX)

Sep 17, 2025 07:01AM Nurix Therapeutics presents preclinical data for GS-6791 IRAK4 degrader

Jul 14, 2025 10:11AM Nurix (NRIX) PT Lowered to $16 at Morgan Stanley

Jul 10, 2025 07:25AM Stifel Reiterates Buy Rating on Nurix (NRIX)

Jul 10, 2025 06:41AM Nurix (NRIX) PT Lowered to $26 at UBS

Jul 10, 2025 06:25AM Goldman Sachs Starts Nurix (NRIX) at Buy

Jul 10, 2025 06:12AM Stifel Reiterates Buy Rating on Nurix (NRIX)

Jul 1, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)

Jun 13, 2025 09:07AM UBS Reiterates Buy Rating on Nurix (NRIX)

Jun 13, 2025 09:02AM Nurix (NRIX) PT Raised to $28 at RBC Capital

Jun 3, 2025 06:26AM Stifel Reiterates Buy Rating on Nurix (NRIX)

Jun 2, 2025 11:14AM Leerink Partners Reiterates Market Perform Rating on Nurix (NRIX)

Jun 2, 2025 07:01AM Sanofi (SNY) Exercises License Extension Option to Nurix’s (NRIX) STAT6 Program

Apr 25, 2025 01:01PM Nurix Therapeutics (NRIX) Presents Positive Preclinical Data

Apr 17, 2025 07:01AM Nurix Therapeutics (NRIX) Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 10, 2025 10:23AM Nurix (NRIX) PT Lowered to $30 at UBS

Apr 9, 2025 08:00AM Nurix (NRIX) PT Lowered to $35 at Stifel

Apr 9, 2025 07:05AM Nurix (NRIX) PT Lowered to $30 at Stephens

Apr 9, 2025 05:28AM Stifel Reiterates Buy Rating on Nurix (NRIX)

Apr 9, 2025 05:15AM BTIG Reiterates Neutral Rating on Nurix (NRIX)

Apr 3, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)

Apr 2, 2025 07:03AM Nurix Therapeutics (NRIX) Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Mar 17, 2025 07:01AM Nurix Therapeutics (NRIX) Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 14, 2025 04:03PM Nurix Therapeutics (NRIX) announces inducement grants

Mar 13, 2025 04:00PM Nurix Therapeutics (NRIX) Appoints Roy D. Baynes to its Board

Jan 29, 2025 10:10AM Nurix (NRIX) PT Raised to $36 at Stifel

Jan 29, 2025 07:59AM Nurix (NRIX) PT Lowered to $28 at Needham

Jan 29, 2025 06:39AM Nurix (NRIX) PT Raised to $36 at H.C. Wainwright

Jan 28, 2025 04:23PM Nurix Therapeutics, Inc. (NRIX) Misses Q4 EPS by 7c

Jan 22, 2025 07:00AM Nurix Therapeutics (NRIX) Appoints John Northcott as Chief Commercial Officer

Dec 22, 2024 04:00AM Barclays shares outlook for Biotech in 2025, names preferred stocks

View Older Stories